Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 26.50p 25.00p 28.00p 26.50p 26.50p 26.50p 0 07:45:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.8 -0.6 -12.0 - 1.47

Aortech (AOR) Latest News

More Aortech News
Aortech Takeover Rumours

Aortech (AOR) Share Charts

1 Year Aortech Chart

1 Year Aortech Chart

1 Month Aortech Chart

1 Month Aortech Chart

Intraday Aortech Chart

Intraday Aortech Chart

Aortech (AOR) Discussions and Chat

Aortech Forums and Chat

Date Time Title Posts
22/8/201616:24Aortech - Interesting Biomaterials Business. Market Cap All Cash2,751
03/7/201517:20Upwards1
19/1/200716:00Aortech with Charts & News6
07/4/200617:46Wakey Wakey! - Aortec in bid talks......70
05/11/200311:47Aortech is an obvious 2-bagger68

Add a New Thread

Aortech (AOR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
26/09/2016 14:29:2025.00112.75O
View all Aortech trades in real-time

Aortech (AOR) Top Chat Posts

DateSubject
27/9/2016
09:20
Aortech Daily Update: Aortech International is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AOR. The last closing price for Aortech was 26.50p.
Aortech International has a 4 week average price of 26.88p and a 12 week average price of 25.65p.
The 1 year high share price is 38p while the 1 year low share price is currently 19.50p.
There are currently 5,557,695 shares in issue and the average daily traded volume is 28 shares. The market capitalisation of Aortech International is £1,472,789.18.
24/2/2016
17:10
spurious: Totally understandable when invested with a serial disappointer like Aor that we all can miss the positive changes taking place and as a result patience is not rewarded. I genuinely believe the changes taking place currently will have a major impact on the share price in the coming months or I would not still be invested Best regards SP
16/9/2015
11:08
spurious: Harrogate As a fellow shareholder of longstanding (some may say long suffering)I understand your caution I am not noted for wild bouts of optimism particularly with Aor however I do recognise a fundamental shift both in sentiment and in what has been achieved over the last 12 months. I feel we are at an inflexion point for the share price which as we all know tends to anticipate events well in advance 12 month results pointed to a profitable stable company now crucially happy with its renegotiated relationship with Biomerics, confident in a ring fenced litigation process and now fully focused in releasing shareholder value through expanding its licencees and at long last attempting to realise the massive opportunity offered by its heart valve( backed by extensive patent protection). Let us wait for the evidence but the signs are already there. Once the evidence is out there the share price will imo be north of £1 and an opportunity missed. The tiny £2m current market cap imo offers a risk/reward ratio substantially in favour of the investor. That value is what I am trying to highlight.It would seem I am not alone Let us hope I am right Regards SP
16/9/2015
09:21
harrogate: It is great that we no longer seem to be at death's door but we should also not get carried away. The £3 share price of 3 years ago was really down to the value we felt we added to St Jude on the leads which turned out to be a complete illusion. My reading of the last RNS was that in terms of any real data on the heart valve we are back to 1999 almost and that there is a massive amount of work to do and won't any IP protection have lapsed by now? I also have not seen any evidence as you say above that " we are rapidly building turnover" there has been little evidence of new licenses of our technology. I am a lot more confident than I was 12 months ago but lots to do. Let's hope the management team are up to it - the are clearly good at fire fighting but that is a different kettle of fish.
15/9/2015
11:08
spurious: Hi George Whether we get an update on progress at the agm or whether that comes some weeks later I am confident we will get news confirming we are in an exciting new chapter built on solid profitable foundations As you point out people forget that the heart valve did represent a £32 million opportunity and if sold on to a major player after successful in house testing/validation/regulatory approval then this figure could easily double So for a relatively modest outlay (borne by its partner) Aor could be sitting on a gold mine. A JV may be the best way to unlock the potential and ring fence costs while offering a share in future profits As Aor pointed out recently much of the testing has already been successfully carried out for the heart valve and it shows potential to be a world beater particularly due to the very significant cost savings over its rivals Aor highlighted the opportunity at results when it announced it was exploring ways of bringing a team together to develop the value Aor is now profitable and rapidly building turnover and profits from a stable/falling cost base Aor as a loss making Co enjoyed a share price in excess of £3 a couple of years ago and while I agree the share price is only a barometer of sentiment and expectation some of that optimism is now being realised in terms of real profits and opportunity The heart valve is in the share price for free so is the potential £1 mil outcome of the ongoing litigation against Mcguire We have a £2m market cap without the risk and negativity of previous years where we enjoyed a cap in excess of £10m as a loss maker with nil turnover Incredible ! Value will out Great time to be an Aor shareholder imo Best wishes SP
14/9/2015
21:32
spurious: Have to echo your sentiments George. I am hoping the agm this month may provide the ideal opportunity for some positive news. Just as the downside on the share price was greatly exaggerated, the corresponding effect on any positive news will be an equally swift and strong rise I am confident we will see a share price well in excess of £1 in a matter of weeks. Value will out
04/9/2015
15:50
spurious: Hi Paul I regret selling Ind way too early, albeit at a good profit and well done for being so patient Biomerics relationship is key and for the first time this appears to be working. I am very hopeful we will see the benefits of this shortly in new increased repeat orders for Elasteon. Throw in a possible JV on the heart valve and a company confident in successfully pursuing a million dollar claim and you certainly have the makings of a multi-bagger. Aor enjoyed a share price in excess of £3 in last couple of years while loss making. It is now making profit. I am confident the share price will soon respond Best regards Patrick
05/6/2014
10:40
spurious: While all shareholders are understandably desperate for results I strongly believe Roy and Eddie are working flat out cutting costs and building relationships to good effect and the current share price only reflects uncertainty and a lack of any real information.I hope we will hear positive news shortly and confirmation the business has not only been stabilised but offers a platform for sustained profitable growth. Any positive news will have a corresponding impact on a share price which currently seems to suggest Aortech were about to go out of business rather than reflecting the determination of Roy and Eddie to successfully drive down costs and provide the basis for future profits from Elasteon sales that await imminent FDA clearance from our partner. The lack of news while frustrating, reflects a desire to only release news that has a material effect on the Co rather than massaging the share price for short term gain.I do feel the coming months will see a substantial re-rating of the share price as confirmation of progress is evidenced. Patience should be rewarded Regards SP
10/11/2012
09:36
gac141: Latest.. It's Getting Ugly As St.Jude Wins Injunction Against AorTech's Threat To Pull Optim Supply November 9, 2012 In short A few weeks ago AorTech's share price was soaring as it looked like it was about to escape from its contract to supply St.Jude subsidiary business Pacesetter with the coating for its Durata ICD leads. Now, however, AorTech's shareprice has dropped almost 50% from its peak three weeks ago as St.Jude wins an injunction against the termination of the contract. Background We covered this unfolding tale in October, here. The story, as far as we're given to believe, relates to the relationship between St.Jude's Pacesetter subsidiary (so St.Jude then) and Scottish company AorTech, the latter being provider of the clever polymer coating that St.Jude is pinning its hopes on as its Durata ICD lead strives manfully to repair the commercial damage done by its predecessor. Anyway, to cut a long story short, AorTech decided that St.Jude had breached its contract, for reasons it didn't disclose at the time. In St.Jude's pursuit of legal countermeasures, proceedings suggested that the breach was for St.Jude placing "excessive supply orders intended to cause AorTech to default on its supply obligations". It also seems the company allegedly broke another agreement entered into when it acquired AorTech's manufacturing assets "by entering into an employment agreement with an AorTech employee at his request". Back to the story, AorTech said it would terminate the supply agreement in the event that the breach(es) was(were) not rectified and clearly believed that this would happen. The contract to supply one of the world's biggest cardiovascular device companies was clearly so bad for AorTech that it's share price shot up on the very thought of its termination. So St.Jude, clearly determined to shore up its supply of its so-called Optim coating, sued AorTech and have now been granted an injunction against the termination of the supply agreement. And why wouldn't St.Jude want the arrangement to continue? It owns the manufacturing assets for the coating material, but not the IP, so that could get messy in the event of a split. It doesn't to our knowledge have an alternative supplier, and even if it did one can only imagine that switching would be a painful process. And finally, it has just announced preliminary results from an analysis of registry data pertaining to Durata which rather supports its long-held view that the device with its AorTech-manufactured coating is performing rather well, with rates of insulation abrasion and mechanical failure of Riata ST Optim and Durata leads appearing to be very low. Find that release here. What happens next? To be honest we've absolutely no idea, but one possibility seems to be that the antagonists may decide it was all a big misunderstanding, have a few too many drinks to patch things up and fall into bed together. AorTech wants to sell and St.Jude has reasons to buy...that's all we're saying.
15/10/2012
18:01
gac141: Could St.Jude And Aortech's End Game Spell Trouble For Durata™ ? October 15, 2012 In short Last week we covered the developing shenanigans regarding Aortech and St.Jude's relationship. And an interesting story it's becoming as the two parties home in on what looks like an inevitable termination early next month. Or, in what may look like rather a long shot at the moment, it may end up as an acquisition. St.Jude have to be hoping so as AorTech's coating technology underpins its Durata™ product. Background According to Aortech International PLC, it's biggest client, St.Jude Medical Inc., has breached the contract under which Aortech supplies the coating on what is one of their most sensitive products, the Durata ICD lead, successor to the troubled Riata family. The coating, branded Elast-Eon™ by AorTech (Optim™ in its St.Jude guise) and proprietary to AorTech, has been supplied under the contract since 2006. Its incorporation into St.Judes ICD leads has seemingly been the biggest contributary factor in fixing the so-called "externalisation" issues suffered by St.Jude's previous generation ICD lead product lines. All good so far then, except that troubles have been looming for a while. As recently as September St.Jude made something of a faux pas by stating publicly that it had "acquired the exclusive intellectual property rights and necessary assets for the manufacture of Optim insulation used in CRM leads". Aortech were quick to point out the fact that St Jude had not acquired the exclusive intellectual property rights to Optim™. St.Jude was forced to issue a retraction of its original statement to this effect. That must have done wonders for relations. Back to the here and now, AorTech remains the sole manufacturer and supplier of the material that St. Jude calls Optim, and retains ownership of the associated intellectual property and know-how. The two companies' closeness extends to St.Jude's purchase from AorTech of the plant and equipment to manufacture Optim, these assets being located in a facility which AorTech leases from St Jude. AorTech continues to use these assets to manufacture Elast-Eon/Optim. Our guess is that somewhere in the entanglement of that particular deal lies the source of the alleged breach, but that remains speculation. In any event it now transpires that the deal might not actually have been all that sweet for AorTech, which is rumoured to have been squeezed on price, to such an extent that it is actually making a loss on every sale. It's perhaps unsurprising then that AorTech's share price has enjoyed a near 50% ramp this morning following the news of its impending likely termination of the St.Jude deal. So where's it all going to end up? It's no secret that AorTech is in the market for a disposal (the share price move points to that too) and that St.Jude is the most likely buyer. Indeed until the recent dispute they, and numerous other parties, large and small, were already at the negotiating table. If it doesn't end well however, St.Jude might just be in a pickle. While the company is issuing its own stout defence of the breach claim, it is also going to some lengths to convince observers that it has both inventory and alternative supply lines for Optim. AorTech obviously thinks not, its posture suggesting it is holding a good hand of cards. AorTech's clearly sees the demand for its technology and it would appear that the markets agree that its stars are lined up for the desired exit. Whether that ends well for St.Jude too remains to be seen.
24/11/2011
17:15
deswalker: zaksab, It's unclear whether we've arrived at this situation by accident or design. I suspect the former but if it's the latter then Frank Maguire is a genius. Basically, we worked with St Jude 5 or 6 years ago. In order to get the interest we absolutely did not get the contract terms we should have done. With hindsight everyone now acknowledges this. Consequently our Turnover has remained lower than it should have done. St Jude got a bargain. But move forward five years we now see that this company is not really about our Turnover at all, it is all about the IP and know-how built up in the company and the importance of this to more than one customer but primarily St Jude. The best analogy I can think of is a drug dealer. Give the stuff away at first, get the market hooked and then ask what you want :o/ Not pleasant I know but that is where we are IMO. St Jude weren't to know 6 years ago just how crucial this material would become to them but they do now. As I say if this situation was engineered back in 2005 then our CEO is a genius but more likely it's just a fortunate accident that is now being considered by management and shareholders alike. The only thing that has changed since the move to the US is most if not all peoples' perception of the business. There might have been a few who had this perception all along (and built big shareholdings as a result) but for most including me this realization about the strength of Aortech's position and its IP has only hit home very recently. For the last two years since I got involved I've been reading and worrying about completely the wrong set of accounts, namely AOR's instead of STJ's. The AOR share price should have tracked St Jude's increasing dependence not its own poor financials IMO. IMO, HTH
Aortech share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20160927 08:45:12